S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
NASDAQ:NTEC

Intec Pharma Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$9.15
$36.20
52-Week Range N/A
Volume988,300 shs
Average Volume543,436 shs
Market Capitalization$8.65 million
P/E RatioN/A
Dividend YieldN/A
Beta0.83

Receive NTEC News and Ratings via Email

Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter.


Intec Pharma logo

About Intec Pharma

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTEC
Employees
40
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$16.18 per share

Profitability

Net Income
$-14,130,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$8.65 million
Next Earnings Date
N/A
Optionable
Optionable

MarketRank

Overall MarketRank

1.49 out of 5 stars

Analyst Opinion: 3.2Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Intec Pharma (NASDAQ:NTEC) Frequently Asked Questions

Is Intec Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intec Pharma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Intec Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NTEC, but not buy additional shares or sell existing shares.
View analyst ratings for Intec Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Intec Pharma?

Wall Street analysts have given Intec Pharma a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intec Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Intec Pharma's earnings last quarter?

Intec Pharma Ltd (NASDAQ:NTEC) issued its quarterly earnings results on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share for the quarter, missing the Zacks' consensus estimate of ($3.48) by $0.36.
View Intec Pharma's earnings history
.

When did Intec Pharma's stock split? How did Intec Pharma's stock split work?

Intec Pharma shares reverse split on Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 27th 2021. An investor that had 100 shares of Intec Pharma stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for NTEC?

3 analysts have issued 12 month target prices for Intec Pharma's shares. Their forecasts range from $52.00 to $52.00. On average, they anticipate Intec Pharma's share price to reach $52.00 in the next twelve months.
View analysts' price targets for Intec Pharma
or view top-rated stocks among Wall Street analysts.

Who are Intec Pharma's key executives?

Intec Pharma's management team includes the following people:
  • Jeffrey A. Meckler, Vice Chairman & Chief Executive Officer
  • Nir Sassi, President & Chief Financial Officer
  • Michael James Newman, Director & Chief Scientific Officer
  • Anna Hotovely-Salomon, Director-Clinical Affairs
  • Walt A. Linscott, Chief Business Officer

What other stocks do shareholders of Intec Pharma own?

When did Intec Pharma IPO?

(NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners served as the underwriters for the IPO.

What is Intec Pharma's stock symbol?

Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC."

Who are Intec Pharma's major shareholders?

Intec Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Morgan Stanley (3.88%) and Morgan Stanley (3.88%). Company insiders that own Intec Pharma stock include Issac Silberman and Pharma Technologies Ltd Dexcel.
View institutional ownership trends for Intec Pharma
.

Which major investors are buying Intec Pharma stock?

NTEC stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, and Morgan Stanley.
View insider buying and selling activity for Intec Pharma
or or view top insider-buying stocks.

How much money does Intec Pharma make?

Intec Pharma has a market capitalization of $0.00. The biotechnology company earns $-14,130,000.00 in net income (profit) each year or ($16.32) on an earnings per share basis.

How many employees does Intec Pharma have?

Intec Pharma employs 40 workers across the globe.

What is Intec Pharma's official website?

The official website for Intec Pharma is www.intecpharma.com.

Where are Intec Pharma's headquarters?

Intec Pharma is headquartered at 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512.

How can I contact Intec Pharma?

Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The biotechnology company can be reached via phone at (722) 586-4657 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.